Author review tools

 Quick Explanation Copied

 Long Explanation

Evidence supporting scientific strength

The supplied publication set suggests broad clinical research activity spanning anesthesiology, surgery, infectious disease, nephrology, genetics, and immunology. The strongest study-level evidence is a randomized, double-blind trial in 117 analyzed participants with non-diabetic stage 3–4 CKD: cholecalciferol improved flow-mediated dilation by 5.49 percentage points versus placebo (95% CI 4.34–6.64) and reduced pulse-wave velocity by 1.24 m/s (95% CI −2.16 to −0.74). However, these were surrogate outcomes from one center, not hard cardiovascular endpoints, and the population excluded diabetic CKD.Randomized CKD vascular-function trial

The 2026 procalcitonin study is sizeable (1,346 suspected sepsis cases), but its diagnostic performance was uneven: AUC was 0.811 for bacterial versus viral cases, yet only 0.609 versus fungal cases, 0.413 versus malaria, and 0.664 versus skin commensals. Its single-center convenience sample, small malaria/fungal groups, possible diagnostic misclassification, and unmeasured renal-function, immunosuppression, and prior-antibiotic confounding limit the broad interpretation that PCT is a “universal” biomarker.Prospective procalcitonin diagnostic study

Critical qualification

The supplied citation metadata is internally inconsistent: one record reports 25 papers, 294 citations, and h-index 10, while OpenAlex lists several different people named Anupam Gupta, including profiles with h-indices of 49, 25, 16, and 10. The medical papers and the computer-science works cannot safely be merged without an ORCID, institution, complete author lists, or verified persistent identifiers. Consequently, the metrics are not reliable evidence about the same individual. The record also does not permit a robust assessment of reproducibility, authorship contribution, retractions, preregistration, data sharing, or independent replication. Confidence in the author-level judgment is therefore moderate-to-low despite several apparently credible studies.

 BGPT Author Review

Scientific Quality

The supplied medical record suggests competent, multidisciplinary clinical research, including randomized and prospective designs. The score is limited by identity ambiguity, incomplete authorship attribution, sparse replication evidence, surrogate endpoints, single-center studies, small subgroup sizes, and several extracted-data inconsistencies. The score does not incorporate the unrelated high-impact computer-science Anupam Gupta profiles.

Communication Quality

The supplied titles and study summaries communicate recognizable clinical questions and comparative designs. Communication quality is reduced by terminology and transcription errors, inconsistent numerical fields, broad claims that exceed some diagnostic results, and insufficient information about reporting completeness.

Author Novelty

The portfolio appears moderately novel through cross-etiology procalcitonin analysis and disease-specific NETosis mechanisms, but much of the clinical work uses established comparative, biomarker, case-report, and supplementation paradigms. Novelty cannot be confidently assigned across the whole portfolio because author identity is unresolved.

Scientific Rigor

There is evidence of rigorous methods in the randomized CKD trial and prospective sepsis study, but rigor is uneven across the supplied portfolio. Main concerns are limited external validation, surrogate outcomes, small mechanistic human samples, model-to-human extrapolation, possible confounding, incomplete data provenance, and apparent extraction errors such as implausible confidence intervals and an inconsistent PTH difference.